Variables | No | RR (95% CI) | I2 | Pa | Pb | |
---|---|---|---|---|---|---|
Design | Retrospective cohort | 10 | 1.72 (1.38–2.14) | 62.2% | 0.005 | 0.395 |
Prospective cohort | 6 | 2.02 (1.57–2.60) | 75.7% | 0.001 | ||
Case–control study | 3 | 3.11(2.47–3.92) | 90.2% | < 0.001 | ||
Region | Europe | 5 | 2.79(2.10–3.69) | 78.2% | 0.001 | 0.014 |
Asia | 12 | 1.49(1.22–1.82) | 27.3% | 0.177 | ||
North America | 2 | 3.47 (2.73–4.41) | 93.5% | < 0.001 | ||
Population | Adults and children | 7 | 2.80 (2.29–3.43) | 88.3% | < 0.001 | 0.303 |
Adults | 12 | 1.80 (1.50–2.15) | 28.4% | 0.167 | ||
Malignancy type | Hematological | 7 | 3.20 (2.54–4.03) | 83.0% | < 0.001 | 0.355 |
Solid or hematological | 12 | 1.81 (1.54–2.14) | 60.9% | 0.003 | ||
FN | Yes | 3 | 1.48 (0.87–2.53) | 0.0% | 0.418 | 0.530 |
No | 16 | 2.21 (1.92–2.54) | 80.8% | < 0.001 | ||
ESBL detection methods | Disk diffusion | 6 | 2.21 (1.72–2.83) | 64.6% | 0.015 | 0.554 |
MicroScan | 4 | 3.99 (3.10–5.15) | 85.9% | < 0.001 | ||
NOS | < 6 | 2 | 0.76 (0.39–1.49) | 16.5% | 0.274 | 0.065 |
≥ 6 | 17 | 2.30 (2.00–2.64) | 77.3% | < 0.001 |